Looking for participants aged 18 to 55 who have trouble with heroin or other opiates to participate in a month-long research study at Columbia University Irving Medical Center evaluating the relationship between brain tasks and memory.
The purpose of this research study is to evaluate how commonly drug overdoses in our community involve fentanyl and xylazine. We know that often drugs such as heroin, oxycontin, and even cocaine and methamphetamine, actually contain these additives, even though the person buying the drugs is not aware.
Columbia University Medical Center is recruiting individuals ages 18-65 who are seeking treatment for opioid use disorder to participate in a research treatment study. For your participation, you'll receive treatment with buprenorphine (either sublingual or injectable) at no cost. Participants will complete an overnight inpatient stay to start…
We are looking for participants for a study on the role of immune response in Parkinsons disease (PD) and Alzheimer's disease (AD). We are inviting people WITH PD, WITH AD, WITH amnestic Mild Cognitive Impairment or WITHOUT PD or AD to come and participate. We will be doing several questionnaires, a motor exam, and a short cognitive assessment, in…
Most neurologists and other clinicians treating people with Parkinson's disease (PD) are still unclear about how best to prescribe exercise despite the fact that it is now axiomatic that exercise is therapeutically beneficial for PD. In contrast, drugs for PD are prescribed with care and specificity due to large scientific investigations showing…
The purpose of this study is to find out if the study medicine called EDIT-301 will help in the treatment of Severe Sickle Cell Disease (SCD) and how safe it is to be used in people. EDIT-301 (study medicine) is a new investigational therapy which uses the patient's own stem cells, modifies them by CRISPR technology, and infuses them back to the…
FoxBioNet ECV-004 is an observational study sponsored by the Michael J. Fox Foundation for Parkinson's Research. The purpose of this study is to investigate a gene called LRRK2. Mutations in the LRRK2 gene are associated with Parkinson's disease (PD), and mutation carriers have greater LRRK2 protein activity. The goal of this study is to identify…
The purpose of this study is to learn about whether the study drug (PF-07209326) is safe and effective in people with sickle cell disease and learn about what the right dose is. We will look at drug levels in the blood, see how fast drug levels rise and fall, and what effects the drug has, all of which are known as the pharmacokinetics (PK) and…
Have an Opioid Use Disorder? We need your help for an inpatient clinical research study! Help the New York State Psychiatric Institute research better treatment options for those with opioid use disorder.You could earn up to $12,017.00.You must meet the following criteria: - Age 18 -59 years old- Have opioid use disorder- Be currently taking an oral daily…
The purpose of this research is to learn how to help parent youth pairs work together to help youth with sickle cell disease take hydroxyurea every day as a daily habit. This study is for children and teens ages 10-18 with Sickle Cell Anemia taking hydroxyurea, and their parents (or guardians). Many children and teens do not use hydroxyurea every day. Daily…
This research study uses MRI scans to compare the effect of two medications on suicidal thoughts and brain activity in people who have opioid use disorder. We hope to develop a better understanding of how well these two medications help depression and suicidal thoughts. You may qualify if you have opioid use disorder and suicidal thoughts. Participation…
Healthy heroin users (men and women, ages 21-59) are needed for an eight-week inpatient study investigating medication effects at the NY State Psychiatric Institute. Earn approximately $6,550 - $7,350.
This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
This study is being done to see if giving your child a lower dose of chemotherapy (drug therapy), than has been used historically in bone marrow transplant, to kill his/her own diseased cells before he/she receives a bone marrow transplant, will possibly result in the permanent control of your child's sickle cell disease. Patients will receive busulfan…